Selpercatinib was granted Breakthrough Therapy Designation by the U.S. Food & Drug Administration in 2018 after initial data from the clinical trial LOXO-292 Investigated to Block RET-altered Tumours (LIBRETTO-001) showed the therapy demonstrated robust anti-tumour activity in a group of RET fusion-positive non small cell lung cancer patients, as well as strong evidence of durability.
Now, the same researchers, led by Alexander Drilon, M.D., of Memorial Sloan Kettering Cancer Center in New York City, report data on a primary analysis set of 105 NSCLC patients on selpercatinib.
The researchers presented their updated data on LIBRETTO-001 today at the IASLC 2019 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer.
The LIBRETTO-001 trial includes 87 sites in 16 countries.
Patients with RET fusion-positive non-small cell lung cancer comprise up to two percent of all NSCLC cases but there are no targeted therapies currently approved for patients with this form of lung cancer.
Selpercatinib (LOXO-292) is an oral and highly selective investigational drug in clinical development for the treatment of patients with cancers that harbour abnormalities in the Rearranged During Transfection gene (RET).
Genomic alterations involving RET, which include fusions and activating point mutations, lead to overactive RET signalling and uncontrolled cell growth.
Researchers presented data from the phase 1/2 LIBRETTO-001 trial, where they noted a high response rate in the primary analysis set of NSCLC patients previously treated with platinum-based chemotherapy, with 68 percent achieving responses and a median duration of response of 20.3 months.
The intracranial objective response rate was 91 percent (n=10/11) for patients with target lesions in the brain at baseline.
In the safety data set of all 531 patients enrolled to the study, 5 treatment-related AEs occurred in ?15 percent of patients: dry mouth, diarrhea, hypertension, increased AST and increased ALT.
Most AEs were grade 1-2. Only 9 of 531 (1.7 percent) patients discontinued LOXO-292 for treatment-related AEs.
“In this large cohort, selpercatinib’s response rate, durability, robust intracranial activity and safety show promise. Furthermore, this continues to confirm that RET fusions are clinically targetable alterations, placing them in the company of activating EGFR/ALK/ROS1 alterations. We are encouraged by this data as there is currently an unmet need to provide genomically tailored therapy to patients with RET fusion-positive NSCLCs.” Drilon reported.